Menu
Search Close

News

Notice of AGM

19th September 2014

Scancell Holdings plc (‘Scancell’ or the ‘Company’), the developer of novel immunotherapies for the treatment of cancer, will host its Annual General Meeting on Tuesday 14 October 2014.

AGM details are as follows:

Date:

Tuesday 14 October 2014

Time:

11.00am

Venue:

Thistle Hotel EMA
East Midlands Airport
Castle Donington
Derby
DE74 2SH

The AGM presentation will include an update on the progress of the SCIB1 clinical programme and will also highlight progress on the development of both the ImmunoBody® and Moditope® platforms.

For Further Information:

Dr Richard Goodfellow, Joint CEO

Professor Lindy Durrant, Joint CEO

Scancell Holdings Plc

Scancell Holdings Plc

+ 44 (0) 20 3727 1000

Christopher Golden/Stephen Keys

Cenkos Securities

+ 44 (0) 20 7397 8900

Mo Noonan/Simon Conway

FTI Consulting

+ 44 (0) 20 3727 1000

About Scancell

Scancell is developing novel immunotherapies for the treatment of cancer based on its ImmunoBody® and Moditope® technology platforms. Scancell’s first ImmunoBody®, SCIB1 is being developed for the treatment of melanoma and is being evaluated in a Phase 1/2 clinical trial. Data from the trial demonstrate that SCIB1, when used as monotherapy, has a marked effect on tumour load, produces a melanoma-specific immune response and highly encouraging survival trend without serious side effects.

Pre-clinical data on a combination of SCIB1 and checkpoint inhibition (blockade of the PD-1 immune checkpoint pathway), has shown enhanced tumour destruction and significantly longer survival times than when either treatment was used alone.

Scancell’s ImmunoBody® vaccines target dendritic cells and stimulate both parts of the cellular immune system; the helper cell system where inflammation is stimulated at the tumour site; and the cytotoxic T-lymphocyte or CTL response where immune system cells are primed to recognise and kill specific cells.

Scancell has also identified and patented a series of modified epitopes that stimulate the production of killer CD4 T cells that destroy tumours without toxicity. The Directors believe that the Moditope® platform could play a major role in the development of safe and effective cancer immunotherapies in the future.

Webcasts, Interviews and Media Coverage

Scancell welcomes strategic new investor Vulpes Life Sciences Fund

Scancell Holdings PLC (LON:SCLP) CEO Cliff Holloway caught up with Proactive London's Andrew Scott following the announcement they'd raised £3.88mln via a placing with a single new investor to help fund the progression of its lead cancer asset into clinical trials.

The Vulpes Life Sciences Fund will now have a 16.67% stake in the company when the shares are issued next Monday.

Thu, 13 Jun 2019 09:53:00

Scancell raises £3.9mln to advance immunotherapy product pipeline

“At Vulpes we are always searching for overlooked companies that have the ability to make significant advances in medical science, with a view to supporting their development over the long term. We believe Scancell fulfil these criteria perfectly.”

Thu, 13 Jun 2019 06:31:00

Scancell exploring new frontiers in cancer research

Here we take a closer look at Scancell, which is at the vanguard of immuno-oncology

Mon, 20 May 2019 09:51:00